期刊文献+

艾司西酞普兰和氯丙咪嗪治疗强迫症的对照研究 被引量:2

Comparative Study of Escitalopram and Clomipramine in the Treatment of Obsessive-compulisive Disorder
下载PDF
导出
摘要 目的评价艾司西酞普兰治疗强迫症的临床疗效和不良反应。方法将符合入组标准的强迫症患者分为研究组和对照组,研究组服用艾司西酞普兰,对照组服用氯丙咪嗪,疗程8周,采用Yale-Brown强迫症量表(Y-BOCS)、汉密尔顿抑郁量表(HAMD)、副反应量表(TESS),分别在治疗前、治疗第2、4、6、8周进行评分。结果有效率研究组与对照组相比无统计学差异(χ2=0.40,P>0.05)。HAMD评分无统计学差异,TESS评分显示在各时间点两组评分均有显著性差异。结论艾司西酞普兰治疗强迫症疗效与氯丙咪嗪相似,但不良反应明显低于氯丙咪嗪。 Objective To explore the clinical efficacy and the side effects of escitalopram in the treatment of obsessive-compulsive disorder.Methods The patients who accorded with the criteria of obsessive-compulsive were divided into study group and control group,the patients in study group were administered with escitalopram,and control group treated with clomipramine for 8 weeks,and evalulated with Yale Brown Obsessive Compulsive Scale(Y-BOCS),Hamilton Depression Scale(HAMD)and Treatment Emergent Symptom Scale(TESS)before treatment and 2,4,6,8 weeks after treatment.Results As far as response rate,there was no statistical difference between the two groups(χ^2=0.40,P〉0.05)as well as HAMD scores,but at each time point,the TESS scores was significant difference between the two groups.Conclusion Escitalopram is as effective as clomipramine,but has less adverse reaction than clomipramine in the treatment of obsessive-compulsive disorder.
作者 李真 王德燧
出处 《中国健康心理学杂志》 2010年第11期1305-1306,共2页 China Journal of Health Psychology
关键词 艾司西酞普兰 氯丙咪嗪 强迫症 Escitalopram Clomipramine Obsessive-compulisive disorder
  • 相关文献

参考文献4

二级参考文献40

  • 1Greist J,Chouinarad G, Duboff E, et al. Doubleblind Parallel comparison of three dosages of sertralin and placebo in outpatients with obsessive-- compulsive disorders[J]. Arch Gen psychiatry , 1995 , 15:289-295.
  • 2郝伟.精神病学[M].北京:人民卫生出版社,2002.137-8.
  • 3MITCHELL PJ,HOGG S.Behavioral effects of escitalopram predict potent antidepressant activity[J].Biol Psychiatry,2001,49(Suppl):S115 -S117.
  • 4MONTGOMERY SA,LOFT H,SANCHEZ C,et al.Escitalopram(S-enantiomer of citalopram):clinical efficacy and onset of action predicted from a rat model[J].Pharmacol Toxicol,2001,88(5):282 -286.
  • 5ROCHAT B,BAUMANN P,AUDUS KL.Transport mechanisms for the antidepressant RS-citalopram in brain microvessel endothelium[J].Brain Res,1999,831 (1/2):229-236.
  • 6ROCHAT B,AMEY M,BAUMANN P.Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography[J].Ther Drug Monit,1995,17 (3):273-279.
  • 7GUTIERREZ M,MENGEL H.Pharmacokinetics of escitalopram[poster][C]//42nd Annual New Clinical Drug Evaluation Unit Meeting,Boca Raton,Jun 10-13,2000.
  • 8VON MOLTKE LL,GREENBLATT DJ,GIANCARLO GM,et al.Escitalopram(S-citalopram)and its metabolites in vitro:cytochromes mediating biotransformation,inhibitory effects,and comparison to R-citalopram[J].Drug Metab Dispos,2001,29 (8):1102-1109.
  • 9GUTIERREZ MM,ROSENBERG J,ABRAMOWITZ W.An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir[J].Clin Ther,2003,25(4):1200-1210.
  • 10RUDBERG I,HENDSET M,UTHUS LH,et al.Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram)[J].Ther Drug Monit,2006,28(1):102-105:

共引文献59

同被引文献20

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部